Respiratory diseases advocate living with severe asthma. (2022)
Attributed to:
Early Assessment of COVID-19 epidemiology and Vaccine/anti-viral Effectiveness (EAVE II)
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2213-2600(22)00013-3
PubMed Identifier: 35038418
Publication URI: http://europepmc.org/abstract/MED/35038418
Type: Journal Article/Review
Volume: 10
Parent Publication: The Lancet. Respiratory medicine
Issue: 2
ISSN: 2213-2600